Inventiva S.A. ADR (IVA) News

Inventiva S.A. ADR (IVA): $14.34

0.48 (+3.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter IVA News Items

IVA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IVA News Highlights

  • 500 - Internal server error
  • Over the past 24 days, the trend for IVA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest IVA News From Around the Web

Below are the latest news stories about Inventiva SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), July 22, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resource

Yahoo | July 22, 2021

Top 6 Differences Between Real Estate And Stock Market You Must Know! - Inventiva

Top 6 Differences Between Real Estate And Stock Market You Must Know! Inventiva

Inventiva | July 1, 2021

The Need For Similar Accounting Standards Across Finance Institutions In 2021 - Inventiva

The Need For Similar Accounting Standards Across Finance Institutions In 2021 Inventiva

Inventiva | June 28, 2021

Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day

Daix (France), June 15, 2021 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company will participate to the upcoming SVB Leerink CybeRx Series: Liver Disease Day, being held virtually on June 17, 2021. During the event, members of the Companys leadership will engage in 1x1 investor meetings.

Intrado Digital Media | June 15, 2021

INVENTIVA: Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day

Daix (France), June 15, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment o

FinanzNachrichten | June 15, 2021

INVENTIVA: Inventiva announces three scientific presentations at the EASL International Liver Congress 2021 and during a KOL webcast event

Two oral presentations showing the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASHthe positive effects of lanifibranor on several biomarkers of disease a

FinanzNachrichten | June 9, 2021

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event

Two oral presentations showing the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASHthe positive effects of lanifibranor on several biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis One poster presentation showing the beneficial effects of the combination treatment of lanifibranor and ACC1/2 inhibitor firsocostat from GileadInventiva will host a dedicated Key Opinion Leader (KOL) webcast event for investors and a

Yahoo | June 9, 2021

Thai Jewellery Enters The Indian Market Again. - Inventiva

Thai Jewellery Enters The Indian Market Again. Inventiva

Inventiva | June 8, 2021

Inventiva to participate at the Jefferies Virtual Healthcare Conference

Daix (France), May 25, 2021 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company will participate to the upcoming Jefferies Virtual Healthcare Conference, being held virtually on June 1-4, 2021. During the event, members of the Companys leadership will present a corporate overview, participate in a fireside chat and engage in 1x1 investor meetings.

GlobeNewswire | May 25, 2021

INVENTIVA: Inventiva to participate at the Jefferies Virtual Healthcare Conference

Daix (France), May 25, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of

FinanzNachrichten | May 25, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5787 seconds.